Nasdaq:COLL
COLLEGIUM PHARMACEUTICAL, INC
A specialty pharma leader with a strong rare disease portfolio, robust cash generation, and a strategic focus on bringing novel treatments to market.
Key Metrics
Investment Thesis
Bull Case
Investors may view Collegium as an attractive opportunity given its robust revenue growth trajectory from $463.9M to $780.6M over the last four years and a healthy cash position of $231.3M. The company's focus on rare diseases offers high margins and limited competition, potentially allowing for pricing power and stable long-term cash generation. With $565.2M in revolver proceeds and minimal capital expenditures of $1.7M, management has significant financial flexibility to expand its pipeline or acquire complementary assets.
Bear Case
Caution is warranted due to the large non-operating loss of $87.0M and a retained earnings deficit of -$101.1M which may signal underlying structural issues or heavy one-time charges. The company's heavy reliance on accounts receivable of $211.3M compared to modest inventory levels could indicate channel stuffing risks or slower collection cycles in the specialty pharma sector. Significant financing outflows of $110.2M and other cash flow from financing of -$700.5M suggest aggressive leverage usage that could become risky if market conditions tighten.
About COLLEGIUM PHARMACEUTICAL, INC
Collegium Pharmaceutical is a leading specialty pharmaceutical company focused on developing and commercializing innovative therapies for rare diseases and chronic conditions. The company primarily serves the United States market with a portfolio of branded products addressing unmet medical needs in oncology, immunology, and other therapeutic areas. Key revenue drivers include its core product line generating approximately $780.6M in 2025 revenue alongside significant cash reserves of $231.3M.
Analysis
Management Discussion
In 2025, Collegium generated $329.3M in operating cash flow while reporting $62.9M in net profit, reflecting a return to profitability after previous years of losses. However, the company recorded a significant non-operating loss of $87.0M and utilized $110.2M in financing cash flows, suggesting ongoing capital structure adjustments or debt refinancing activities. Despite strong revenue growth from $463.9M in 2022 to $780.6M in 2025, investors should scrutinize the composition of non-operating expenses and the sustainability of current profit margins.
Industry Overview
The specialty pharmaceutical industry is characterized by high barriers to entry, complex regulatory landscapes, and a focus on unmet medical needs in rare diseases and chronic conditions. Companies in this space often rely on proprietary mechanisms of action and strong intellectual property portfolios to maintain market exclusivity and pricing power. Success in this sector requires navigating FDA approval processes, securing favorable reimbursement rates from payers, and managing commercial partnerships effectively.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $463.9M | $566.8M | $631.4M | $780.6M |
| Cost of Revenue | $254.4M | $240.6M | $254.1M | $317.3M |
| Gross Profit | $209.5M | $326.2M | $377.3M | $463.3M |
| Operating Expenses | $176.2M | $159.2M | $207.4M | $283.6M |
| Operating Income | $33.3M | $167.0M | $169.9M | $179.6M |
| R&D | $4.0M | $0 | $0 | — |
| G&A | $172.2M | $159.2M | $210.4M | $284.8M |
| Stock-Based Comp | $22.9M | $27.1M | $32.4M | $41.9M |
| Depreciation | $2.7M | $3.5M | $3.9M | $4.2M |
| Amortization | — | — | — | $221.9M |
| Other OpEx | $0 | $0 | $-2.9M | $-1.2M |
| Non-Operating Income | $-62.2M | $-91.2M | $-71.3M | $-87.0M |
| Interest Expense | $63.2M | $83.3M | — | — |
| Pre-Tax Income | $-28.8M | $75.7M | $98.6M | $92.6M |
| Income Tax | $-3.8M | $27.6M | $29.4M | $29.7M |
| Continuing Ops | $-25.0M | $48.2M | $69.2M | $62.9M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-25.0M | $48.2M | $69.2M | $62.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-25.0M | $48.2M | $69.2M | $62.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $420.0M | $537.6M | $482.3M | $691.4M |
| Cash & Equivalents | $173.7M | $238.9M | $70.6M | $231.3M |
| Marketable Securities | — | $71.6M | $92.2M | $155.4M |
| Accounts Receivable | $183.1M | $179.5M | $228.5M | $211.3M |
| Inventory | $46.5M | $32.3M | $35.6M | $40.9M |
| Prepaid Expenses | $16.7M | $15.2M | $30.4M | $32.6M |
| Other Current Assets | $0 | $0 | $25.0M | $19.9M |
| Long-Term Assets | $754.1M | $605.7M | $1.18B | $965.4M |
| PP&E (Net) | $19.5M | $16.0M | $14.3M | $12.0M |
| Intangibles | $567.5M | $421.7M | $891.4M | $669.5M |
| Goodwill | $133.7M | $133.9M | $162.3M | $145.9M |
| Operating Leases | $6.9M | $6.0M | $5.8M | $4.2M |
| Other LT Assets | $26.6M | $28.1M | $107.4M | $133.8M |
| Total Assets | $1.17B | $1.14B | $1.66B | $1.66B |
| Current Liabilities | $433.7M | $457.9M | $509.5M | $440.0M |
| Accounts Payable | $3.5M | $8.7M | $3.9M | $10.7M |
| Current Leases | $1.1M | $988.0K | $1.3M | $1.4M |
| Deferred Revenue | — | — | — | $667.0K |
| Taxes Payable | — | $2.1M | $8.5M | $3.3M |
| Other Current Liab | $393.0M | $408.5M | $423.7M | $361.5M |
| Long-Term Liabilities | $545.6M | $490.0M | $925.2M | $915.1M |
| LT Operating Leases | $7.1M | $6.1M | $5.5M | $4.1M |
| Other LT Liab | $538.5M | $483.8M | $909.7M | $901.9M |
| Total Liabilities | $979.3M | $947.9M | $1.43B | $1.36B |
| Shareholders' Equity | $194.8M | $195.4M | $228.8M | $301.7M |
| Paid-In Capital | $538.1M | $565.9M | $590.3M | $625.0M |
| Retained Earnings | $-281.3M | $-233.2M | $-164.0M | $-101.1M |
| AOCI | — | $14.0K | $55.0K | $319.0K |
| Total L&E | $1.17B | $1.14B | $1.66B | $1.66B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-25.0M | $48.2M | $69.2M | $62.9M |
| Non-Cash Adjustments | $183.0M | $240.1M | $182.0M | $273.3M |
| Working Capital Changes | $-33.7M | $-13.5M | $-46.3M | $-6.9M |
| Cash from Operations | $124.2M | $274.7M | $205.0M | $329.3M |
| Capital Expenditures | $1.6M | $461.0K | $1.7M | $1.7M |
| Cash from Investing | $-573.7M | $-70.8M | $-287.8M | $-63.5M |
| Share Buybacks | $14.1M | $75.0M | $60.0M | $25.1M |
| Cash from Financing | $436.7M | $-140.2M | $-60.6M | $-110.2M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-12.7M | $63.8M | $-143.4M | $155.5M |
| Beginning Cash | $189.0M | $176.2M | $240.0M | $96.6M |
| Ending Cash | $176.2M | $240.0M | $96.6M | $252.2M |
Frequently Asked Questions
How does COLLEGIUM PHARMACEUTICAL, INC make money?
The company's revenue is driven by its core branded product portfolio focused on rare diseases such as Sialidosis, Chediak-Higashi Syndrome, and other orphan indications. Additional segments include emerging pipeline assets in oncology and immunology that contribute to future growth potential. Non-operating income losses of $87.0M suggest potential restructuring costs or write-downs affecting the overall segment performance.
What are the main risks for COLL?
The company faces significant regulatory risks as rare disease approvals can be delayed or modified by the FDA, impacting revenue recognition timelines. High reliance on a concentrated product portfolio creates vulnerability to pricing pressures, formulary exclusions, or patent expirations that could sharply reduce cash flows. The substantial non-operating loss of $87.0M and retained earnings deficit indicate potential underlying operational challenges or one-time charges affecting long-term stability.
What is COLL's competitive advantage?
Collegium possesses a deep scientific expertise in rare diseases with proprietary compounds that address high-need, low-competition therapeutic areas. The company maintains a strong balance sheet with $231.3M in cash and equivalents providing flexibility for M&A or R&D investments without immediate dilution concerns. Its specialized commercial infrastructure is optimized for niche markets where patient advocacy groups play a critical role in adoption.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.